Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Project Oncology®
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Project Oncology®
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Medical News

Medical News
Severe Malnutrition Predicts Worse Survival in Lung Cancer
08/28/2026
Read more
Medical News
Survival Improvements in Recurrent and Metastatic ESCC Cohort
08/28/2026
Read more
Medical News
Metabolic Syndrome Raises Mortality Risk in Breast Cancer Survivors
08/28/2026
Read more
Medical News
ROI Dilation Disrupts Pediatric Brain Tumor ADC Radiomics
08/24/2026
Read more

CME/CE

Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
1.00 credit
- Sagar Lonial, MD, FACP
1.00 credit
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 credits 4 episodes
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD

Programs

Exploring Combination Treatment in ER+/HER2- Breast Cancer
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Wassim Mchayleh, MD, MBA, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Wassim Mchayleh, MD, MBA, FACP
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD; Mohamed Abdelbaki, MD
- Shelina Ramnarine, PhD
- Mohamed Abdelbaki, MD
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD; John Mascarenhas, MD
- Shelina Ramnarine, PhD
- John Mascarenhas, MD
- Marina Kremyanskaya, MD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Douglas A. Tremblay, MD